NCT04530968

Brief Summary

Following severe traumatic brain injury, patients may remain unconscious for many years. It is the intestinal microbiome and metabolomics analysis comparing differentially intestinal microflora and metabolites between patients with chronic disorder of consciousness and controls so far. The investigators have mature data analysis technology. The obtained results provide new insight into understanding the molecular mechanisms underlying the chronic disorder of consciousness

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2018

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 13, 2018

Completed
2.4 years until next milestone

First Submitted

Initial submission to the registry

July 29, 2020

Completed
1 month until next milestone

First Posted

Study publicly available on registry

August 28, 2020

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2022

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2023

Completed
Last Updated

May 7, 2024

Status Verified

July 1, 2020

Enrollment Period

4.5 years

First QC Date

July 29, 2020

Last Update Submit

May 6, 2024

Conditions

Keywords

Disorder of Consciousnessmicrobiomemetabolomics

Outcome Measures

Primary Outcomes (1)

  • metabolic profiling and Intestinal microbial spectrum

    A comprehensive metabolic profile from plasma was obtained with targeted metabolomics analysis and untargeted and targeted lipidomics analysis; intestinal microbial spectrum was obetained from fecal by16S rRNA gene sequencing among HCs, EMCS, MCS and VS groups.

    1 month

Secondary Outcomes (3)

  • Coma Recovery Scale-Revised(CRS-R)

    30 minutes before samples collection

  • Glasgow Outcome Scale (GOS)

    6 months

  • Indicators of brain connectivity by EEG

    On the same day as collecting the samples

Study Arms (4)

Emerged from Minimally Conscious State (EMCS)

Emerged from Minimally Conscious State (EMCS): recovery of functional object uses or communication from chronic

Other: No intervention

Minimally conscious state (MCS)

Minimally conscious state (MCS): have reproducible signs of awareness and exhibit fluctuations in consciousness

Other: No intervention

Vegetative state (VS)

Vegetative state (VS): can open their eyes and preserve sleep-wake cycles, but unaware of themselves and their surroundings

Other: No intervention

Healthy controls (HCs)

Healthy controls (HCs)

Other: No intervention

Interventions

No intervention

Emerged from Minimally Conscious State (EMCS)Healthy controls (HCs)Minimally conscious state (MCS)Vegetative state (VS)

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with chronic disorder of consciousness were recruited at the rehabilitation units of Hangzhou Hospital of Zhejiang Armed Police Corps, China and Hangzhou Mingzhou Brain Rehabilitation Hospital.

You may qualify if:

  • Patients ages 18 to 80 years old;
  • Patients had a history of severe Traumatic brain injury (TBI);
  • Patients had awakened from a coma (indicating preserved sleep-wake cycles), including vegetative state and minimally consciousness state;
  • Patients stay unconscious for more than 1 month.

You may not qualify if:

  • Patients with disorders of consciousness caused by other inducements;
  • Other neurological or psychiatric conditions prior to the current brain injury;
  • Persistent seizure-like activity, inhibition or seizure inhibition;
  • The patients had taken a sedative barbiturate neuroleptics or antidepressants within one month;
  • The clinical state is unstable, and there are signs of spontaneous recovery or deterioration within 1 week;
  • The patients have taken gastrointestinal motility drugs or other drugs affecting gastrointestinal motility in the past month;
  • Had taken antibiotics and probiotics in the past month;
  • Patients with intestinal diseases such as colon cancer, ulcerative colitis or crohn's disease;
  • Patients with acute infectious diseases or liver dysfunction

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

SCIEX QTRAP 5500 liquid chromatograph / triple quadrupole mass spectrometer.

Hangzhou, Zhejiang, 310002, China

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Plasma for metabolites and lipids;Fecal samples for microbiome and metabolites.

MeSH Terms

Conditions

Consciousness Disorders

Condition Hierarchy (Ancestors)

Neurobehavioral ManifestationsNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and SymptomsNeurocognitive DisordersMental Disorders

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 29, 2020

First Posted

August 28, 2020

Study Start

March 13, 2018

Primary Completion

September 1, 2022

Study Completion

April 1, 2023

Last Updated

May 7, 2024

Record last verified: 2020-07

Data Sharing

IPD Sharing
Will not share

Locations